Morgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70

Benzinga Newsdesk www.benzinga.com Positive 55.4%

Neg 0% Neu 0% Pos 55.4%

Morgan Stanley analyst Sean Laaman initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $70.